{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:06:56Z","timestamp":1788520016351,"version":"build-2803163510"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,13]]},"abstract":"<jats:p>Distant-metastatic hepatocellular carcinoma (DM-HCC) represents the terminal stage of liver cancer, characterized by the spread of cancer cells from the primary tumor site in the liver to distant organs, such as the lungs, bones, or lymph nodes. This study aims to develop a predictive model for assessing cancer-specific survival (CSS) in patients with DM-HCC. We extracted data from the surveillance, epidemiology, and end results (SEER) database for 651 patients initially diagnosed with DM-HCC between 2010 and 2017. The patients were randomly allocated to the training and validation cohorts at a 7:3 ratio. Cox regression analysis was used to identify predictors of CSS. The nomogram was validated using concordance index (C-index), receiver operating characteristic (ROC) curve, calibration curves, and decision curve analysis. Multivariate Cox regression analysis showed that alpha-fetoprotein (AFP) expression, grade, T stage, lung metastasis, surgery, radiation, and chemotherapy were independent predictors of CSS. A predictive model was established based on these factors, and a nomogram method was used for visualization. The C-index of the nomogram were 0.721 and 0.726 in the training and validation sets, respectively. In the training set, the time-dependent area under the curve (AUC) values were 0.796, 0.797, and 0.766 at 4, 8, and 12 months, respectively. In the validation set, time-dependent AUC values were 0.767, 0.771, and 0.834 at 4, 8, and 12 months, respectively. Calibration curves indicated good consistency between the actual observed values and the nomogram predictions for CSS, while decision curve analysis demonstrated that the nomogram has good clinical application value. Simultaneously, a risk classification system was established, perfectly categorizing DM-HCC patients into 2 risk groups: low- and high-risk groups. We developed a nomogram with high accuracy for predicting the prognosis of patients with DM-HCC, which is important for enhancing the survival and prognosis of this patient population.<\/jats:p>","DOI":"10.1097\/md.0000000000042834","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T03:00:41Z","timestamp":1750215641000},"page":"e42834","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Establishment of a prognostic nomogram and risk stratification system for patients with distant-metastatic hepatocellular carcinoma: A population-based study"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3708-7987","authenticated-orcid":false,"given":"Qiuhan","family":"Heng","sequence":"first","affiliation":[{"name":"Department of the School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Leng","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Clinical Medical College of the Fifth People\u2019s Hospital Affiliated to Chengdu University of Traditional Chinese Medicine, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of the School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1428-4935","authenticated-orcid":false,"given":"Hua","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250618","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250618","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management.","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R3-20250618","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study.","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol"},{"key":"R4-20250618","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.4251\/wjgo.v15.i11.1874","article-title":"Conditional survival probability of distant-metastatic hepatocellular carcinoma: a population-based study.","volume":"15","author":"Yang","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"R5-20250618","doi-asserted-by":"crossref","first-page":"m3544","DOI":"10.1136\/bmj.m3544","article-title":"New advances in the diagnosis and management of hepatocellular carcinoma.","volume":"371","author":"Yang","year":"2020","journal-title":"BMJ"},{"key":"R6-20250618","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","article-title":"Precision treatment in advanced hepatocellular carcinoma.","volume":"42","author":"Yang","year":"2024","journal-title":"Cancer Cell"},{"key":"R7-20250618","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines:management of hepatocellular carcinoma.","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"R8-20250618","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/17474124.2022.2150610","article-title":"Low-grade hepatocellular carcinoma characteristics, a practical nomogram and risk stratification system: a SEER population-based study.","volume":"16","author":"Yang","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"S23","key":"R9-20250618","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1002\/cncr.29049","article-title":"The surveillance, epidemiology, and end results (SEER) program of the national cancer institute.","volume":"120","author":"Cronin","year":"2014","journal-title":"Cancer"},{"key":"R10-20250618","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1002\/hep.26130","article-title":"Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma.","volume":"57","author":"Wang","year":"2013","journal-title":"Hepatology"},{"key":"R11-20250618","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2009.25.9895","article-title":"Advanced hepatocellular carcinoma: which staging systems best predict prognosis.","volume":"28","author":"Huitzil-Melendez","year":"2010","journal-title":"J Clin Oncol"},{"key":"R12-20250618","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3389\/fonc.2019.01329","article-title":"Prognostic model to predict cancer-specific survival for patients with gallbladder carcinoma after surgery: a population-based analysis.","volume":"9","author":"He","year":"2019","journal-title":"Front Oncol"},{"key":"R13-20250618","doi-asserted-by":"crossref","first-page":"6370946","DOI":"10.1155\/2020\/6370946","article-title":"Prognostic evaluation for patients over 45 years old with gallbladder adenocarcinoma resection: a SEER-based nomogram analysis.","volume":"2020","author":"Li","year":"2020","journal-title":"Biomed Res Int"},{"key":"R14-20250618","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/cells9061370","article-title":"Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment.","volume":"9","author":"Pi\u00f1ero","year":"2020","journal-title":"Cells"},{"key":"R15-20250618","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","article-title":"Liver transplantation for hepatocellular carcinoma: a model including \u03b1-fetoprotein improves the performance of Milan criteria.","volume":"143","author":"Duvoux","year":"2012","journal-title":"Gastroenterology"},{"key":"R16-20250618","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/MEG.0000000000000551","article-title":"Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.","volume":"28","author":"Pi\u00f1ero","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R17-20250618","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma.","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"R18-20250618","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/liv.13159","article-title":"Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America.","volume":"36","author":"Pi\u00f1ero","year":"2016","journal-title":"Liver Int"},{"key":"R19-20250618","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2017.06.026","article-title":"Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies.","volume":"67","author":"Bruix","year":"2017","journal-title":"J Hepatol"},{"key":"R20-20250618","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1111\/j.1440-1746.2005.03919.x","article-title":"Clinical features of hepatocellular carcinoma with extrahepatic metastases.","volume":"20","author":"Natsuizaka","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"R21-20250618","doi-asserted-by":"crossref","first-page":"563","DOI":"10.6004\/jnccn.2017.0059","article-title":"NCCN guidelines insights: hepatobiliary cancers, version 1.2017.","volume":"15","author":"Benson","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"R22-20250618","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/SLA.0b013e31829291e9","article-title":"Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact.","volume":"259","author":"Utsunomiya","year":"2014","journal-title":"Ann Surg"},{"key":"R23-20250618","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s10585-014-9641-x","article-title":"Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions.","volume":"31","author":"Lee","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"R24-20250618","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1002\/cncr.25960","article-title":"Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors.","volume":"117","author":"Uchino","year":"2011","journal-title":"Cancer"},{"key":"R25-20250618","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3748\/wjg.v13.i3.414","article-title":"Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma.","volume":"13","author":"Uka","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R26-20250618","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1002\/cam4.1738","article-title":"The impact of liver resection on survival outcomes of hepatocellular carcinoma patients with extrahepatic metastases: a propensity score matching study.","volume":"7","author":"Mao","year":"2018","journal-title":"Cancer Med"},{"key":"R27-20250618","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R28-20250618","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3350\/cmh.2022.0391","article-title":"Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity.","volume":"29","author":"Iwamoto","year":"2023","journal-title":"Clin Mol Hepatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T03:00:46Z","timestamp":1750215646000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":28,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042834","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]}}}